Tempus AI, Inc. TEM
TEM Rating
TEM Rating Factors
TEM Company Overview
Tempus AI, Inc. is a healthcare technology and precision medicine company focused on applying artificial intelligence, clinical data analytics, and molecular diagnostics to improve patient care and therapeutic development. The company operates primarily in the oncology sector but has expanded into adjacent areas including cardiology, radiology, infectious disease, and mental health. Tempus combines multimodal healthcare data—including genomic sequencing, clinical records, imaging, and laboratory information—with AI-enabled software tools to support physicians, researchers, and life sciences companies.
The company’s primary revenue drivers include genomic testing services, data licensing and analytics for pharmaceutical and biotechnology companies, and AI-enabled clinical software platforms. Tempus serves healthcare providers, academic medical centers, biopharmaceutical companies, and researchers. Its strategic positioning is rooted in the scale of its proprietary clinical and molecular data platform, integration of AI capabilities into clinical workflows, and relationships with major health systems and drug developers. Founded in 2015 by Eric Lefkofsky, Tempus evolved from an oncology-focused precision medicine company into a broader AI-enabled healthcare infrastructure platform, culminating in its public listing on Nasdaq under the ticker TEM in 2024.
TEM Income Statement
TEM Balance Sheet
TEM Price History
TEM Valuation
TEM Dividends and Shares
TEM Corporate Info
Suite 510
Chicago, IL 60654